Experts warn wireless rivals Sprint and T-Mobile have a tough road ahead to secure antitrust clearance for their proposed merger that appears to be in the works, reports say.
According to analysts, share drops experienced by both companies show how competitive issues surrounding the merger, which would reduce the number of operators from four to three, show how investors’ top concern over the deal is regulatory scrutiny.
Regulators in the US have already shown skepticism about wireless consolidation, especially since the US Department of Justice blocked AT&T’s proposed acquisition of T-Mobile in 2011.
The $32 billion merger, orchestrated by Sprint owner Softbank and T-Mobile owner Deutsche Telekom, will have to convince antitrust and communications regulators that the deal would benefit consumers and not significantly harm market competition. And it’s a long shot, according to experts.
While not naming Sprint and T-Mobile specifically, DOJ assistant antitrust attorney general Bill Baer expressed last January that a major wireless merger would not easily gain approval.
”It’s going to be hard for someone to make a persuasive case that reducing four firms to three is actually going to improve competition for the benefit of American consumers,” he said.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas